Study of Memantine Augmentation in Severe Obsessive-Compulsive Disorder

Mass General Brigham logo

Mass General Brigham

Status

Completed

Conditions

Obsessive-Compulsive Disorder

Study type

Observational

Funder types

Other

Identifiers

NCT00869505
2008-P-000461

Details and patient eligibility

About

Memantine is a glutamate receptor antagonist that has been reported to reduce Obsessive-Compulsive Disorder (OCD) symptoms in case studies of treatment-resistant individuals. The investigators hypothesized that memantine is an effective augmenting agent to standard intensive residential treatment of severe OCD. An intent-to-treat, single-blinded, naturalistic case-control design is employed. The sample includes subjects receiving standard treatment at the McLean/ MGH Intensive Residential Treatment (IRT) program, half of whom also receive memantine augmentation. Admission, monthly and discharge measures of OCD, depression and psychosocial functioning are collected by raters blinded to augmentation status. Matched controls are selected based upon gender, initial OCD severity, psychosocial functioning, and timing of admission. Descriptive and comparative analyses are conducted via SPSS, statistical significance is defined at p\<0.05, clinically significant response is defined by a 25% reduction, and 'marked response' is defined by a 50% improvement in Yale-Brown Obsessive Compulsive severity (Y-BOCS) scores, using a last-observation-carried-forward approach. The Clinical Global Improvement (CGI) scale captures global clinical change.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Consecutive patients of IRT at the OCD Institute who agreed to augmentation with memantine.
  • Consecutive patients of IRT at the OCD Institute who were not offered augmentation with memantine and who were matched according to OCD severity, gender, and psychosocial functioning.

Exclusion criteria

  • Subjects offered memantine augmentation who did not provide voluntary consent.

Trial design

0 participants in 2 patient groups

Case Group
Description:
Intensive Residential Treatment with memantine augmentation
Control Group
Description:
Intensive Residential Treatment without memantine augmentation

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems